Procept BioRobotics today released results from a slew of studies of its Aquablation therapy provided with its Aquabeam robotic system, touting the device as durable, safe and effective.
The AquaBeam system uses a robotically controlled waterjet to ablate prostate tissue without needing heat, the Redwood Shores, Calif.-based company said
Results from the trials were presented at the American Urological Association’s annual meeting, Procept BioRobotics said.
Procept BioRobotics presented one-year data from the WATER II study exploring the use of Aquablation therapy in 101 men with prostates 80 to 150 mL in size. Results from the study showed that Aquablation was a safe surgical alternative for patients with large prostate glands, with durable outcomes reported at one year alongside fast operating times, short hospitalizations and maintenance of antegrade ejaculatory function.
The company also presented two-year follow-up data from the WATER study comparing the safety and efficacy of Aquablation therapy to transurethral resection of the prostate. Results showed longer term, durable evidence of the safety and effectiveness of the device in treating patients with lower urinary tract symptoms due to BPH with prostates between 30 and 80 mL in size, Procept BioRobotics said.
In its last presentation, the company touted single-center results from a consecutive, 180-patient cohort treated with Aquablation therapy between September 2017 and June 2018, with results showing safety and efficacy measures consistent with the WATER and WATER II outcomes in a real-life setting.
“These longer-term study results, and the recent addition of Aquablation therapy to the AUA surgical practice guidelines for BPH, position Aquablation therapy as a new standard of care for patients suffering from BPH. Aquablation therapy is the only BPH treatment that democratizes BPH surgery by delivering predictable and reproducible outcomes from day one, independent of prostate anatomy, size or complexity – and it does so regardless of surgeon experience,” prez & CEO Nikolai Aljuri said in a press release.
In March, Hydrocision said that it inked an exclusive worldwide licensing deal to allow Procept Biorobitics to use its pump cartridge technology for urological applications.
